In the United States, an estimated 20,000 new cases of liverand biliary tract cancer are diagnosed annually.1 Biliary tractcancer is the second most common primary hepatobiliary cancer,after hepatocellular cancer. Approximately 7500 new cases ofbiliary tract cancer are diagnosed per year; about 5000 of theseare gallbladder cancer, and between 2000 and 3000 are bile-ductcancers.1 Biliary tract cancers have traditionally been dividedinto cancers of the gallbladder, the extrahepatic bile ducts,and the ampulla of Vater, whereas intrahepatic bile-duct cancershave been classified as primary liver cancers.2 The term "cholangiocarcinoma"was originally intended to refer only . . . [Full Text of this Article]
Pathological Features
Risk Factors
Molecular Aspects
Diagnosis
Treatment and Survival
Surgery
Radiation
Chemotherapy
Other Palliative Treatments
Future Directions
Source Information
From the Mayo Clinic, Rochester, Minn.
Address reprint requests to Dr. de Groen at the Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.
References
Related Letters:
Biliary Tract Cancers
Figueras J., Valls C., Jaurrieta E., de Groen P. C.
Extract |
Full Text
N Engl J Med 2000;
342:663-664, Mar 2, 2000.
Correspondence
This article has been cited by other articles:
Sainani, N. I., Catalano, O. A., Holalkere, N.-S., Zhu, A. X., Hahn, P. F., Sahani, D. V.
(2008). Cholangiocarcinoma: Current and Novel Imaging Techniques. RadioGraphics
28: 1263-1287
[Abstract][Full Text]
Mott, J. L., Bronk, S. F., Mesa, R. A., Kaufmann, S. H., Gores, G. J.
(2008). BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Molecular Cancer Therapeutics
7: 2339-2347
[Abstract][Full Text]
Randi, G., Malvezzi, M., Levi, F., Ferlay, J., Negri, E., Franceschi, S., La Vecchia, C.
(2008). Epidemiology of biliary tract cancers: an update. Ann Oncol
0: mdn533v1-mdn533
[Abstract][Full Text]
Andreotti, G., Chen, J., Gao, Y.-T., Rashid, A., Chen, B. E., Rosenberg, P., Sakoda, L. C., Deng, J., Shen, M.-C., Wang, B.-S., Han, T.-Q., Zhang, B.-H., Yeager, M., Welch, R., Chanock, S., Fraumeni, J. F. Jr., Hsing, A. W.
(2008). Polymorphisms of Genes in the Lipid Metabolism Pathway and Risk of Biliary Tract Cancers and Stones: A Population-Based Case-Control Study in Shanghai, China. Cancer Epidemiol. Biomarkers Prev.
17: 525-534
[Abstract][Full Text]
Tan, J. C. C., Coburn, N. G., Baxter, N. N., Kiss, A., Law, C. H. L.
(2008). Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study. Ann. Surg. Oncol.
15: 600-608
[Abstract][Full Text]
Khan, S A, Miras, A, Pelling, M, Taylor-Robinson, S D
(2007). Cholangiocarcinoma and its management. Gut
56: 1755-1756
[Full Text]
Iyer, R. V., Gibbs, J., Kuvshinoff, B., Fakih, M., Kepner, J., Soehnlein, N., Lawrence, D., Javle, M. M.
(2007). A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study. Ann. Surg. Oncol.
14: 3202-3209
[Abstract][Full Text]
Yonemoto, N., Furuse, J., Okusaka, T., Yamao, K., Funakoshi, A., Ohkawa, S., Boku, N., Tanaka, K., Nagase, M., Saisho, H., Sato, T.
(2007). A Multi-center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer. Jpn J Clin Oncol
37: 843-851
[Abstract][Full Text]
Herberger, B., Puhalla, H., Lehnert, M., Wrba, F., Novak, S., Brandstetter, A., Gruenberger, B., Gruenberger, T., Pirker, R., Filipits, M.
(2007). Activated Mammalian Target of Rapamycin Is an Adverse Prognostic Factor in Patients with Biliary Tract Adenocarcinoma. Clin. Cancer Res.
13: 4795-4799
[Abstract][Full Text]
Matull, W.-R., Khan, S. A., Pereira, S. P.
(2007). Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. JNCI J Natl Cancer Inst
99: 407-407
[Full Text]
Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R., Pfeiffer, R. M.
(2007). Response: Re: Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States. JNCI J Natl Cancer Inst
99: 407-408
[Full Text]
Slattery, J. M., Sahani, D. V.
(2006). What Is the Current State-of-the-Art Imaging for Detection and Staging of Cholangiocarcinoma?. The Oncologist
11: 913-922
[Abstract][Full Text]
Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R., Pfeiffer, R. M.
(2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.. JNCI J Natl Cancer Inst
98: 873-875
[Abstract][Full Text]
Lee, H. Y., Kim, S. H., Lee, J. M., Kim, S.-W., Jang, J.-Y., Han, J. K., Choi, B. I.
(2006). Preoperative Assessment of Resectability of Hepatic Hilar Cholangiocarcinoma: Combined CT and Cholangiography with Revised Criteria. Radiology
239: 113-121
[Abstract][Full Text]
Karikari, C. A., Mullendore, M., Eshleman, J. R., Argani, P., Leoni, L. M., Chattopadhyay, S., Hidalgo, M., Maitra, A.
(2005). Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Molecular Cancer Therapeutics
4: 1860-1866
[Abstract][Full Text]
Reinhardt, M. J., Strunk, H., Gerhardt, T., Roedel, R., Jaeger, U., Bucerius, J., Sauerbruch, T., Biersack, H.-J., Dumoulin, F. L.
(2005). Detection of Klatskin's Tumor in Extrahepatic Bile Duct Strictures Using Delayed 18F-FDG PET/CT: Preliminary Results for 22 Patient Studies. JNM
46: 1158-1163
[Abstract][Full Text]
Knox, J. J., Hedley, D., Oza, A., Feld, R., Siu, L. L., Chen, E., Nematollahi, M., Pond, G. R., Zhang, J., Moore, M. J.
(2005). Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. JCO
23: 2332-2338
[Abstract][Full Text]
Park, J.-S., Oh, S.-Y., Kim, S.-H., Kwon, H.-C., Kim, J.-S., Jin-Kim, H., Kim, Y.-H.
(2005). Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. Jpn J Clin Oncol
35: 68-73
[Abstract][Full Text]
Kristiansen, T. Z., Bunkenborg, J., Gronborg, M., Molina, H., Thuluvath, P. J., Argani, P., Goggins, M. G., Maitra, A., Pandey, A.
(2004). A Proteomic Analysis of Human Bile. Mol. Cell. Proteomics
3: 715-728
[Abstract][Full Text]
Rea, D. J., Munoz-Juarez, M., Farnell, M. B., Donohue, J. H., Que, F. G., Crownhart, B., Larson, D., Nagorney, D. M.
(2004). Major Hepatic Resection for Hilar Cholangiocarcinoma: Analysis of 46 Patients. Arch Surg
139: 514-525
[Abstract][Full Text]
Yeh, C.-N., Maitra, A., Lee, K.-F., Jan, Y.-Y., Chen, M.-F.
(2004). Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis
25: 631-636
[Abstract][Full Text]
Kornek, G. V., Schuell, B., Laengle, F., Gruenberger, T., Penz, M., Karall, K., Depisch, D., Lang, F., Scheithauer, W.
(2004). Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol
15: 478-483
[Abstract][Full Text]
Nakajima, T., Takayama, T., Miyanishi, K., Nobuoka, A., Hayashi, T., Abe, T., Kato, J., Sakon, K., Naniwa, Y., Tanabe, H., Niitsu, Y.
(2003). Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-{pi}-Specific Inhibitor O1-Hexadecyl-{gamma}-glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester. J. Pharmacol. Exp. Ther.
306: 861-869
[Abstract][Full Text]
Hansel, D. E., Rahman, A., Hidalgo, M., Thuluvath, P. J., Lillemoe, K. D., Shulick, R., Ku, J.-L., Park, J.-G., Miyazaki, K., Ashfaq, R., Wistuba, I. I., Varma, R., Hawthorne, L., Geradts, J., Argani, P., Maitra, A.
(2003). Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. Am. J. Pathol.
163: 217-229
[Abstract][Full Text]
Khan, S A, Carmichael, P L, Taylor-Robinson, S D, Habib, N, Thomas, H C
(2003). DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma. Gut
52: 586-591
[Abstract][Full Text]
Lai, G.-H., Zhang, Z., Sirica, A. E.
(2003). Celecoxib Acts in a Cyclooxygenase-2-independent Manner and in Synergy with Emodin to Suppress Rat Cholangiocarcinoma Growth in Vitro through a Mechanism Involving Enhanced Akt Inactivation and Increased Activation of Caspases-9 and -3. Molecular Cancer Therapeutics
2: 265-271
[Abstract][Full Text]
Schrumpf, E, Boberg, K M
(2003). Hepatic and extrahepatic malignancies and primary sclerosing cholangitis. Gut
52: 165-165
[Full Text]
Makower, D., Rozenblit, A., Kaufman, H., Edelman, M., Lane, M. E., Zwiebel, J., Haynes, H., Wadler, S.
(2003). Phase II Clinical Trial of Intralesional Administration of the Oncolytic Adenovirus ONYX-015 in Patients with Hepatobiliary Tumors with Correlative p53 Studies. Clin. Cancer Res.
9: 693-702
[Abstract][Full Text]
Khan, S A, Davidson, B R, Goldin, R, Pereira, S P, Rosenberg, W M C, Taylor-Robinson, S D, Thillainayagam, A V, Thomas, H C, Thursz, M R, Wasan, H
(2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut
51: vi1-9
[Full Text]
Fiorentino, M., Altimari, A., D'Errico, A., Gabusi, E., Chieco, P., Masetti, M., Grigioni, W. F.
(2001). Low p27 Expression Is an Independent Predictor of Survival for Patients with Either Hilar or Peripheral Intrahepatic Cholangiocarcinoma. Clin. Cancer Res.
7: 3994-3999
[Abstract][Full Text]
Hocqueloux, L., Molina, J.-M., Gervais, A.
(2000). Cholangiocarcinoma and AIDS-Related Sclerosing Cholangitis. ANN INTERN MED
132: 1006-1007
[Full Text]
Figueras, J., Valls, C., Jaurrieta, E., de Groen, P. C.
(2000). Biliary Tract Cancers. NEJM
342: 663-664
[Full Text]